KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Current Leases (2019 - 2025)

Fulgent Genetics (FLGT) has disclosed Current Leases for 7 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 1.32% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 1.32% year-over-year, with the annual reading at $1.5 million for FY2025, 1.32% up from the prior year.
  • Current Leases hit $1.5 million in Q4 2025 for Fulgent Genetics, down from $1.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $6.1 million in Q4 2022 to a low of $1.0 million in Q2 2021.
  • Historically, Current Leases has averaged $2.2 million across 5 years, with a median of $1.5 million in 2024.
  • Biggest five-year swings in Current Leases: surged 257.42% in 2021 and later crashed 63.53% in 2024.
  • Year by year, Current Leases stood at $1.8 million in 2021, then skyrocketed by 235.08% to $6.1 million in 2022, then plummeted by 35.47% to $4.0 million in 2023, then plummeted by 63.53% to $1.4 million in 2024, then grew by 1.32% to $1.5 million in 2025.
  • Business Quant data shows Current Leases for FLGT at $1.5 million in Q4 2025, $1.5 million in Q3 2025, and $1.2 million in Q2 2025.